Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
Pancreatic: Metastatic: 1st Line: NAPOLI 3

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas

Title
Ipsen D-US-60010-001 (Pancreatic)
Study Title

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas

Site Link
Malignancy
Pancreas Adenocarcinoma
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
1st
Investigational Agent
Irinotecan liposome injection (Nal-IRI)
Drug Class
Liposomal chemotherapy
PI
Axel Grothey, MD
Sponsor
Ipsen
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically confirmed adenocarcinoma of pancreas not previously treated in metastatic setting
  • Initial diagnosis of metastatic disease < or = 6 weeks prior to screening
  • Measurable disease
  • ECOG PS 0-1
  • Adequate hepatic, hemtologic, and renal function
  • No prior therapy in adjuvant setting unless adjuvant therapy was completed at least 12 months prior to metastatic diagnosis
  • No CNS metastases
Objective
  • Primary- OS
  • Secondary- PFS, ORR
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Adenocarcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
Yes
X